Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of ...

In the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.

Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

To Know in detail about the Retinal Vein Occlusion ... drugs for the treatment of Retinal Vein Occlusion, including LUCENTIS (ranibizumab, Roche/Novartis), EYLEA (aflibercept, Regeneron ...

They also will evaluate advances in imaging and current and emerging therapies for the treatment and management of retinal vein occlusion. Upon successful completion of this educational activity ...

Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand ... and Macular Edema following Retinal Vein Occlusion (RVO). The decision of the European ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of EYLEA HD (aflibercept) Injection 8 mg for treating ...

Regeneron Pharmaceuticals has reported positive outcomes from the Phase III QUASAR trial of Eylea HD (aflibercept ... with macular oedema following retinal vein occlusion (RVO).